ES2187946T3 - Uso de interleucina-15. - Google Patents

Uso de interleucina-15.

Info

Publication number
ES2187946T3
ES2187946T3 ES98912417T ES98912417T ES2187946T3 ES 2187946 T3 ES2187946 T3 ES 2187946T3 ES 98912417 T ES98912417 T ES 98912417T ES 98912417 T ES98912417 T ES 98912417T ES 2187946 T3 ES2187946 T3 ES 2187946T3
Authority
ES
Spain
Prior art keywords
antibodies
alpha
inhibiting
compounds
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98912417T
Other languages
English (en)
Inventor
Johan Adriaan Marc Grooten
Hans Peter Raf Dooms
Walter Charles Fiers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2187946(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Application granted granted Critical
Publication of ES2187946T3 publication Critical patent/ES2187946T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a la utilización de la IL-15 o de variantes activos de la misma y/o compuestos mejoradores de la actividad de la IL-15 para la fabricación de una composición farmacéutica para manipular las células memoria del sistema inmune, tal como para manipular la viabilidad y/o la sensibilidad de las células memoria. El compuesto mejorador de la actividad de la IL-15 es por ejemplo un lipopolisacárido (LPS). La invención se refiere además a la utilización de compuestos que inhiben o eliminan la actividad de la IL-15 para la fabricación de una composición farmacéutica para manipular las células memoria del sistema inmune. Los compuestos de inhibición o eliminación son por ejemplo anticuerpos anti-IL-15, anticuerpos anti-IL- 15R{sub,alfa}, fragmentos de estos anticuerpos, por ejemplo el fragmento Fab o F(ab¿){sub,2}, IL-15-R{sub,alfa}soluble, proteínas de fusión que constan de IL-15R{sub,alfa} y del fragmento Fc, compuestos, por ejemplo péptidos, que se unen y/o inhiben el receptor funcional de la IL-15, oligonucleótidos antisentido IL-15.
ES98912417T 1997-02-21 1998-02-23 Uso de interleucina-15. Expired - Lifetime ES2187946T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97200515 1997-02-21

Publications (1)

Publication Number Publication Date
ES2187946T3 true ES2187946T3 (es) 2003-06-16

Family

ID=8228040

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98912417T Expired - Lifetime ES2187946T3 (es) 1997-02-21 1998-02-23 Uso de interleucina-15.

Country Status (9)

Country Link
US (3) US6344192B1 (es)
EP (2) EP0971728B1 (es)
AT (2) ATE295736T1 (es)
AU (1) AU6726698A (es)
DE (2) DE69810091T2 (es)
DK (1) DK1273304T4 (es)
ES (1) ES2187946T3 (es)
WO (1) WO1998036768A1 (es)
ZA (1) ZA981478B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192935B1 (en) 1993-03-08 2007-03-20 Amgen Inc. Polynucleotides encoding epithelium-derived T-cell factor and uses thereof
IL126919A0 (en) * 1998-11-05 1999-09-22 Univ Ben Gurion Antisense oligomer
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
EP1927657A3 (en) * 2000-05-11 2008-10-22 Baylor Research Institute Compositions and methods for producing antigen-presenting cells
DE60138222D1 (de) 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
US7041302B2 (en) * 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
DK1606318T3 (da) 2003-03-26 2009-11-02 Apogenix Gmbh Forbedrede Fc-fusionsproteiner
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
CU23472A1 (es) * 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
CA2590401C (en) 2004-10-08 2015-04-21 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Adoptive immunotherapy with enhanced t lymphocyte survival
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
EP1984505B1 (en) 2006-01-13 2019-12-25 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
CA2691785C (en) * 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes of il-15 and il-15ralpha and uses thereof
EP3135294B1 (en) 2009-08-14 2020-06-03 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Use of il-15-il-15 receptor heterodimers to treat lymphopenia
EP2619229B1 (en) 2010-09-21 2016-04-06 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
KR102539359B1 (ko) 2013-04-19 2023-06-02 싸이튠 파마 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
KR102503476B1 (ko) 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
KR102392142B1 (ko) 2016-10-21 2022-04-28 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
US20250243279A1 (en) 2023-10-17 2025-07-31 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747024A (en) * 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
PT789588E (pt) * 1994-11-17 2005-05-31 Univ South Florida Processo para a producao de um medicamento para o tratamento de imunodeficiencia secundaria
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
CA2231603C (en) 1995-10-17 2009-04-21 Wayne State University Chicken interleukin-15 and uses thereof
US5870759A (en) * 1996-10-09 1999-02-09 Oracle Corporation System for synchronizing data between computers using a before-image of data
US6065018A (en) * 1998-03-04 2000-05-16 International Business Machines Corporation Synchronizing recovery log having time stamp to a remote site for disaster recovery of a primary database having related hierarchial and relational databases
US6356917B1 (en) * 1998-07-17 2002-03-12 Ncr Corporation Monitoring and raising alerts for database jobs
US6553392B1 (en) * 1999-02-04 2003-04-22 Hewlett-Packard Development Company, L.P. System and method for purging database update image files after completion of associated transactions
US6728879B1 (en) * 1999-06-02 2004-04-27 Microsoft Corporation Transactional log with multi-sector log block validation

Also Published As

Publication number Publication date
DE69830257D1 (de) 2005-06-23
EP1273304A2 (en) 2003-01-08
ATE295736T1 (de) 2005-06-15
ZA981478B (en) 1998-08-24
DK1273304T3 (da) 2005-09-12
US20020182178A1 (en) 2002-12-05
EP0971728B1 (en) 2002-12-11
WO1998036768A1 (en) 1998-08-27
EP0971728A1 (en) 2000-01-19
AU6726698A (en) 1998-09-09
DK1273304T4 (da) 2009-08-31
US20070134718A1 (en) 2007-06-14
EP1273304A3 (en) 2003-04-23
DE69830257T3 (de) 2009-10-15
DE69810091D1 (de) 2003-01-23
DE69830257T2 (de) 2006-02-02
US6344192B1 (en) 2002-02-05
ATE229342T1 (de) 2002-12-15
EP1273304B2 (en) 2009-07-15
DE69810091T2 (de) 2003-10-09
EP1273304B1 (en) 2005-05-18

Similar Documents

Publication Publication Date Title
DK1273304T3 (da) Anvendelse af interleukin 15
AU1332099A (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
NL300220I1 (nl) Immunoglobuline varianten voor specifieke FC-epsilon receptoren.
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
TR199900267T2 (xx) GnRH-L�kotoksin kimeralar�.
HUT74845A (en) Antibody purification
ATE542138T1 (de) Her-2-bindungsantagonisten
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
ATE131069T1 (de) Composition comprising at least two different antibodies or fragments thereof.
WO2000039154A8 (de) Peptide des at1-rezeptors und ihre verwendung bei präeklampsie und maligner hypertonie
DK0815141T3 (da) Antistof mod et fusionspolypeptid omfattende en histidinandel
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
IL86710A0 (en) Polypeptide receptor for interleukin-2,antibodies against this polypeptide and pharmaceutical compositions containing the same
NZ237533A (en) Monoclonal antibodies which bind to oncostatin m, cell lines producing them
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
RU94026276A (ru) Рецепторы интерлейкина-12 и антител
AU2002323894A1 (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk